Puma Biotechnology Inc · NASDAQ:PBYI
Puma Biotechnology — Q1 2023 Earnings Presentation
8 slides from Puma Biotechnology's earnings presentation, May 4, 2023
Slide 1: Puma Biotechnology Earnings Call Commercial Update
Puma Biotechnology Earnings Call Commercial Update May 4, 2023
Slide 2: Forward-Looking Safe-Harbor Statement
Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could ca
Slide 3: Puma's Pharmacy and Distributor Network
Puma’s Pharmacy and Distributor Network Hub Services Specialty Pharmacy Network (SP) Acaria Health Accredo CVS ONCO 360 Patients Optum / Biologics Diplomat Sites of Care Specialty Distributor Network (SD) Academic Hospitals McKesson Community Hospitals ASD/Oncology Supply Physician Practices Cardina
Slide 4: ~$47 Million net NERLYNX revenue in Q1'23
~$47 Million net NERLYNX revenue in Q1’23 Quarterly Net Revenue (in $MM) 61.1 58.7 53.8 53.5 54.3 53.7 52.6 51.3 50.8 50.0 51.0 48.6 48.8 49.3 48.9 45.6 45.8 46.8 43.4 40.7 36.0 20.1 6.1 Copyright 2023 Puma Biotechnology 4
Slide 5: 2,849 Ex-factory bottles were sold in Q1'23
2,849 Ex-factory bottles were sold in Q1’23 Bottles Sold (SP + SD) by Quarter 5,538 4,936 4,935 4,799 4,791 4,696 4,452 4,035 3,728 3,611 3,517 3,585 3,454 3,247 3,354 3,200 3,197 3,323 2,947 2,849 2,680 2,137 675 Includes Commercial SP and SD Copyright 2023 Puma Biotechnology 5
Slide 6: ~64% of patients in Q1'23 started at a reduced dose
~64% of patients in Q1’23 started at a reduced dose* ** % of Patients starting at reduced dose 67.9% 65.4% 64.0% 64.0% 61.5% 59.4% 54.9% 42.4% 37.7% 38.7% 32.8% 30.0% 31.0% 28.0% 19.0% 12.0% 11.0% 6.0% 7.0% 4.0% 2.0% 2.0% 3.0% *Reduced dose defined as fewer than 6 pills per day ** FDA approved dose-
Slide 7: Rest of World Partnerships – Timelines
Rest of World Partnerships – Timelines Region Partner Regulatory Approvals Commercial Launches • 2019 – Ext. Adj. in Australia, Singapore • 2020 – Singapore • 2020 – Ext. Adj. in Brunei, Malaysia, New Zealand Australia / SE Asia • Q2 2021 – Malaysia • Q2 2022 – Ext. Adj. in the Philippines • Q3 / Q4
Slide 8: Puma Biotechnology
Puma Biotechnology Earnings Call Commercial Update May 4, 2023